



I. AMENDMENTS

In the Specification:

Please amend the first paragraph of page 1, to recite as follows:

"This application is the National Stage of International Application No. PCT/US00/20007, filed July 21, 2000, which in turn claims priority the benefit under 35 U.S.C. § 119(e) to the following U.S. provisional applications, Serial Nos.: 60/153,855, filed September 14, 1999 and 60/145,364, filed July 22, 1999, the contents of which are hereby incorporated by reference into the present disclosure."

Please amend the heading of the paragraph appearing on page 43, line 24 as follows:

C6 Fluoro uridine and C4 ~~hydrozone~~ hydrazone based compounds.

Please amend the paragraph appearing on page 52, lines 12 to 22, as follows:

"E. RT-PCR analysis of matched normal and human tissues. Transcript levels of human thymidylate synthase transcripts in colon cancer tissues and matched normal normal colong tissues were quantified by using RT-PCR. Oligonucleotide primers for amplification of the human thymidylate synthase and B-actin were designed as follows: thymidylate synthase sense primer (SEQ ID NO:1) 5'-GGGCAGATCCAACACATCC-3' (corresponding to bases 208-226 of thymidylate synthase cDNA sequence, Genbank Accession No. X02308), antisense primer (SEQ ID NO:2) 5'-GGTCAACTCCCTGTCCTGAA-3' (corresponding to bases 564-583), β -actin sense primer (SEQ ID NO:3) 5'-GCCAACACAGTGCTGTCTG-3' (corresponding to bases 2643-2661 of β -actin gene sequence, Genbank Accession No. M10277) and antisense primer (SEQ ID NO:4) 5'-CTCCTGCTTGCTGATCCAC-3' (corresponding to bases 2937-2955)."

Please amend the paragraph appearing on page 54, lines 1 to 9, as follows:

“G. Construction of GFP-TS expression vector. A cDNA fragment encoding conserved region of human thymidylate ~~Synthase~~ synthase (amino acids 23 to 313) was obtained by PCR amplification using following primers: Sense primer, (SEQ ID NO: 5) 5'-CGGAAGCTTGAGCCGCGTCCGCCGCA-3' and antisense primer, (SEQ ID NO: 6) 5'-GAAGGTACCCTAAACAGCCATTTCCA-3'. The cDNA was cloned into HindIII and KpnI sites of mammalian expression vector pEGFP-C3 (Clontech Laboratories[.], Inc., Palo Alto, CA), in-frame with GFP sequence. The cDNA insert was confirmed by DNA sequencing.”

Please add the following sequence listing to the application papers.

In the Abstract:

Please substitute the attached abstract for the one filed with the application papers. The new abstract recites:

This invention provides methods for using novel substituted pyrimidine compounds, derivatives and analogs thereof to treat diseases such as cancer. Examples of compounds and derivatives for use in the methods are (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninylphosphoramidate and (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninyl monophosphate.

In the Figures:

Please substitute the attached Figure 6 for that originally filed with the application papers.